Semaglutide (Ozempic) linked to fewer bone fractures despite greater weight loss

A recent study on semaglutide, commonly known as Ozempic or Wegovy, reveals an intriguing benefit for individuals managing type 2 diabetes: it appears to significantly reduce the risk of bone fractures even as it promotes substantial weight loss. Researchers examined data from almost 60,000 adults and found that those on semaglutide had about 15% fewer bone fractures compared to those using other weight-loss drugs. This finding is particularly significant because it suggests that semaglutide may not only help with weight management but also bolster bone health, providing a dual advantage for patients.